The Compass
Let’s go on a walk together
The Compass is the place for us to share our thoughts and opinions about market access, health economics, and policy issues.
Featured
Update – CY 2025 Final Rule for the Medicare Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems
CMS recently released proposed Contract Year 2025 Medicare payment rates for hospital outpatient and ambulatory surgical center sites of care. The 60-day comment period is now open, and interested parties have until September 9 to comment on the proposed payment rates. For additional information on the proposed payment rates and related new policies, please click […]
Proposed 2025 Medicare Hospital Inpatient Prospective Payment System Update
On April 10, 2024, the Centers for Medicare & Medicaid Services (CMS) issued the fiscal year (FY) 2025 Medicare hospital inpatient prospective payment system (IPPS) and long-term care hospital prospective payment system (LTCH PPS) proposed rule. This proposed rule outlines the policies and payment rate updates that will govern Medicare reimbursement for inpatient hospital services […]
BluePath Solutions Acquires Qualia Bio, LLC
BluePath’s initial acquisition expands its product and service offerings in the biopharmaceutical commercialization services sector. BluePath Solutions, a Los Angeles based health economics and value communication consulting firm announced today that it has acquired Qualia Bio, LLC. Qualia Bio is a specialty healthcare consulting firm with a focus on healthcare policy, market access, and reimbursement. […]
Out-of-pocket cost by cancer stage at diagnosis in commercially insured patients in the United States
Patients diagnosed with cancer may face significant financial toxicity, specifically out-of-pocket (OOP) costs related to medical care. Diagnosis and treatment of cancer at earlier stages may reduce this burden. To better understand the potential impact of earlier diagnosis on patient OOP, our colleagues recently published an analysis using integrated claims-clinical data to estimate OOP costs […]
Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa Trial
In a recently published microcosting analysis using trial healthcare resource utilization data, our colleagues estimated post-infusion costs with the chimeric antigen receptor (CAR) T cell therapy, idecabtagene vicleucel (ide-cel), for relapsed/refractory multiple myeloma patients over a 2-year period. Findings suggest most costs were incurred in the initial treatment period of the first month post-infusion and […]
Estimating the Lifetime Medical Cost Burden of an Allogeneic Hematopoietic Cell Transplantation Patient
Allogeneic hematopoietic cell transplantation (allo-HCT) has the potential for curative outcomes in a variety of hematologic malignancies but are often associated with adverse events, specifically chronic graft versus host disease (GVHD) that results in significant financial toxicity for the payer, provider and patient. Despite several economic evaluations, there is limited evidence on the lifetime burden […]
Time duration and health care resource use during cancer diagnoses in the United States: A large claims database analysis
Our colleagues recently participated in one of the first large-scale claims analyses to date on estimating the time to diagnosis across a range of cancer types. The recent article, published in the Journal of Managed Care Pharmacy (JMCP), found that almost 16% of patients newly diagnosed with cancer waited longer than 6 months to receive […]
Systematic Review of Signs and Symptoms Associated with HSCT-TMA
Our colleagues recently participated in the first systematic literature review and meta-analysis on the signs and symptoms associated with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). The recent open access publication published in Transplantation and Cellular Therapy provides a robust synthesis of currently available evidence. The findings will improve our understanding of HSCT-TMA, a complex […]
A Model to Estimate Cytokine Release Syndrome and Neurological Event Management Costs Associated With CAR T-Cell Therapy
With the marketplace flush with Chimeric antigen receptor (CAR) T-cell therapies to treat relapsed/refractory large B-cell lymphoma (LBCL), one of the key clinical and economic differentiators may be the risk of cytokine release syndrome (CRS) and neurological events (NE). Our recent publication aimed to focus solely on this key feature of treatment with the aim […]
Real-world assessment: effectiveness and safety of extended-release calcifediol and other vitamin D therapies for secondary hyperparathyroidism in CKD patients
A recent publication by our colleagues uses real world data to demonstrate the real world effectiveness of a recently approved therapy while maintaining safe outcomes. Extended-release calcifediol (ERC), active vitamin D hormones and analogs (AVD) and nutritional vitamin D (NVD) are commonly used therapies for treating secondary hyperparathyroidism (SHPT) in adults with stage 3–4 chronic […]
